Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab Extension Study in Hidradenitis Suppurativa
NCT04179175Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2020
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in hidradenitis suppurativa (HS) (5 arms), sponsored by Novartis. Primary endpoints: Time to Loss of Response at 104 weeks and Incidence Rate of Participants Achieving Loss of Response at 104 weeks. Started Mar 2020; status: completed.
02
Drugs
secukinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT04179175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179175.